Hypertension
dc.contributor.author | Schellack, Natalie | |
dc.contributor.author | Padayachee, N. | |
dc.contributor.email | natalie.schellack@up.ac.za | en_US |
dc.date.accessioned | 2023-02-07T10:06:10Z | |
dc.date.available | 2023-02-07T10:06:10Z | |
dc.date.issued | 2022 | |
dc.description.abstract | This article provides an overview of the changes that have taken place in the diagnosis and management of hypertension over the past decade. Hypertension remains a widespread condition seen in South Africa. The approach to managing hypertension includes necessary lifestyle modifications and a decisive, stepwise escalation process in the pharmacotherapeutic management thereof. Most guidelines are still promoting thiazide diuretics to be the initial (first-line) drug of choice, with the addition of other suitable antihypertensive agents, if necessary, and according to any relevant comorbid conditions. | en_US |
dc.description.department | Pharmacology | en_US |
dc.description.librarian | am2023 | en_US |
dc.description.uri | http://www.sapj.co.za/index.php/sapj | en_US |
dc.identifier.citation | Schellack, N. & Padayachee, N. 2022, 'Hypertension', SA Pharmaceutical Journal, vol. 89, no. 1, pp. 19-27. | en_US |
dc.identifier.issn | 2221-5875 (print) | |
dc.identifier.issn | 2220-1017 (online) | |
dc.identifier.uri | https://repository.up.ac.za/handle/2263/89213 | |
dc.language.iso | en | en_US |
dc.publisher | Medpharm Publications | en_US |
dc.rights | © Medpharm. This article is licensed under a This article is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.5 South Africa License. | en_US |
dc.subject | Hypertension | en_US |
dc.subject | Antihypertensive agents | en_US |
dc.subject | Fixed-dose combination therapy | en_US |
dc.subject | Angiotensin II-receptor blockers | en_US |
dc.subject | Angiotensin-converting enzyme inhibitors | en_US |
dc.subject | Calcium-channel blockers | en_US |
dc.title | Hypertension | en_US |
dc.type | Article | en_US |